Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended PEG Interferon Alfa-2b in Solid Tumors
NCT03554005Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 1997
- Primary completion
- Mar 2001
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
Phase 1, open-label trial of peginterferon alfa-2b in solid tumor (6 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced an Adverse Event up to 42 Weeks and Number of Participants Who Discontinued Treatment Due to an Adverse Event up to 40 Weeks. Started Dec 1997; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03554005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554005.